Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

NCT01069120 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

27

Enrollment

INDUSTRY

Sponsor class

Stopped Repros stopped study due to safety and FDA placed study on hold

Conditions

Uterine Fibroids

Interventions

DRUG: Proellex
DRUG: Proellex

Sponsor

Repros Therapeutics Inc.